04:49 AM EDT, 06/03/2024 (MT Newswires) -- Immutep ( IMMP ) said Sunday it has entered a clinical trial collaboration and supply agreement with Merck ( MRK ) to evaluate eftilagimod alfa in combination with Keytruda and chemotherapy to treat metastatic non-small cell lung cancer in a phase III trial.

Under the agreement, Immutep ( IMMP ) will conduct the study, which will enroll 750 patients globally, with Merck ( MRK ) supplying Keytruda, the company said.

The agreement allows both companies to pursue marketing authorization of the combination and to market their respective compounds with a relevant label indication. The companies also retain the commercial rights to their respective compounds, Immutep ( IMMP ) said.